Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress
Reported Earlier, MediciNova Announces Two Abstracts Regarding MN-001 And MN-002 Accepted For Presentation At The 92nd EAS 2024 Congress
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that two abstracts entitled "STUDY PROTOCOL TO EVALUATE MN-001'S (TIPELUKAST) EFFICACY, SAFETY AND TOLERABILITY IN SUBJECTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), HYPERTRIGLYCERIDEMIA (HTG) AND TYPE-2 DIABETES MELLITUS (T2DM)" and "MN-002, THE METABOLITE OF MN-001(TIPELUKAST) PROMOTES MACROPHAGE CHOLESTEROL EFFLUX" have been accepted and selected for poster presentation at the 92nd European Atherosclerosis Society (EAS) 2024 Congress to be held May 26-29, 2024.
在納斯達克全球市場（納斯達克股票代碼：MNOV）和東京證券交易所標準市場（代碼編號：4875）上市的生物製藥公司MedicinOVA, Inc. 今天宣佈，兩份題爲 “評估 MN-001（TIPELUKAST）對非酒精性脂肪肝病（NAFLD）、高甘油三酯血癥（HTG）和 TYPE-2 受試者的療效、安全性和耐受性的研究協議” 的摘要 “糖尿病（T2DM）” 和 “MN-002，MN-001（TIPELUKAST）的代謝物，促進巨噬細胞膽固醇外流” 已被接受併入選海報展出第92屆歐洲動脈粥樣硬化學會（EAS）2024年大會將於2024年5月26日至29日舉行。